Your institution may have access to this item. Find your institution then sign in to continue.
Title
FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality.
Abstract
The article discusses that U.S. Food and Drug Administration has issued a new boxed warning for duvelisib about the increased risk for serious side effects and death with this PI3K inhibitor, based on the result of the DUO clinical trial.